Steroid Nasal Sprays Do Not Increase LDL Cholesterol Levels
Intranasal corticosteroid sprays do not increase LDL cholesterol or affect lipid metabolism at recommended therapeutic doses. The evidence consistently demonstrates that modern intranasal corticosteroids have minimal systemic absorption and no clinically meaningful metabolic effects.
Why Lipid Levels Are Not Affected
The key reason intranasal corticosteroids don't impact cholesterol is their extremely low systemic bioavailability. Second-generation formulations (mometasone furoate, fluticasone propionate, fluticasone furoate, and ciclesonide) have systemic bioavailability of less than 1% due to extensive first-pass hepatic metabolism 1. This minimal systemic exposure makes metabolic effects on lipids essentially impossible at therapeutic doses.
While systemic glucocorticoids (oral or injectable steroids) can alter lipid metabolism and increase LDL cholesterol, this mechanism does not apply to intranasal formulations because the drug concentration reaching the systemic circulation is negligible 2.
What the Guidelines Say About Systemic Effects
Major rhinitis management guidelines from 2008 comprehensively reviewed adverse effects of intranasal corticosteroids and made no mention of lipid abnormalities or cholesterol elevation as a concern 3. The documented systemic effects they monitored included:
- HPA axis suppression (not consistently demonstrated at standard doses)
- Growth effects in children (minimal with modern formulations at recommended doses)
- Bone density changes (limited data, no consistent effect)
- Ocular effects like cataracts or glaucoma (no increased risk at standard doses)
The 2025 sinusitis guidelines similarly confirm that long-term intranasal steroid use has not been shown to impact systemic cortisol levels 4, further supporting the absence of metabolic effects including lipid changes.
Safety Profile Focused on Local, Not Metabolic Effects
The most recent comprehensive safety review from 2026 explicitly states that although systemic glucocorticoid exposure has been associated with alterations in lipid metabolism, currently available intranasal corticosteroids demonstrate minimal systemic exposure, making clinically relevant metabolic effects unlikely under recommended therapeutic conditions 2.
The documented adverse effects are overwhelmingly local rather than systemic 5, 1:
- Most common: Epistaxis (nosebleeds), nasal irritation, dryness, burning sensation
- Rare: Nasal septal perforation with prolonged use
- Systemic effects: Essentially absent at recommended doses
Clinical Bottom Line
You can confidently reassure patients that intranasal corticosteroid sprays will not affect their cholesterol levels or require lipid monitoring. The pharmacokinetic properties of these medications—with their minimal systemic absorption—make metabolic effects on LDL cholesterol biologically implausible at therapeutic doses.
If a patient is concerned about cholesterol, focus the discussion on actual risk factors like diet, exercise, and oral medications rather than their nasal spray, which poses no lipid-related risk.